Explore the exciting world of CRISPR Therapeutics(NASDAQ: CRSP) with our expert analysts

Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Jan. 29, 2025.

In this Motley Fool Scoreboard episode, we'll be delving into the exciting world of CRISPR Therapeutics (NASDAQ:CRSP) with our expert analysts. Join them as they discuss the latest market trends and highlight potential investment opportunities.

But first, let's see what one analyst is recommending for investing $1,000 right now.

Where to invest $1,000 right now?

Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

See the full ranking now.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now … and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005 … if you invested $1,000 at the time of our recommendation, you'd have $736,343!

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002. Don't miss out on the latest top 10 list, available when you join Stock Advisor.

Get started investing with our analyst team today.

Now, let's get started with CRISPR Therapeutics.

One analyst is recommending investors buy CRISPR Therapeutics stock. Despite a recent surge of over 100% in 2024, the biotech's stock price is still down 70% from its all-time high reached in November 2021.

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has soared. The company exceeded analysts' expectations for both earnings and revenue, and it also raised its outlook for the full year.

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-thalassemia and sickle cell disease. Its flagship product, an experimental treatment for beta-thalassemia called bentradicimab, is currently in Phase 3 testing.

Earlier this month, CRISPR announced that it had achieved promising results in a mid-stage clinical trial of bentradicimab in treating sickle cell disease. The company observed a complete response rate of 50% in patients with beta-thalassemia who had received at least 12 months of treatment with bentradicimab.

In the third quarter, CRISPR posted a net loss of $108.7 million, compared to analysts' estimate of $117.5 million. The company reported earnings per share of $0.40, whereas analysts expected $0.37. Revenue for the period amounted to $140.9 million, exceeding analysts' projections of $133 million.

For the full year, CRISPR now anticipates a net loss in the range of $360 million to $390 million, narrower than the prior outlook of $400 million to $430 million. Analysts had estimated a net loss of $372 million. The biotech also raised its revenue forecast for the year to a band of $540 million to $570 million, up from the previous projection of $490 million to $520 million. Analysts had estimated revenue of $541 million.

Despite the promising results and optimistic outlook, one analyst remains cautious on CRISPR stock. Here's why.

Now playing video

portion

Hello, and welcome to this edition of Motley Fool Top Buys. I'm Karl Thiel, and I'll be joined by one of The Motley Fool's expert analysts as we take a closer look at one stock that could be a promising addition to your portfolio.

We'll also be highlighting the ten best stocks to buy right now, according to The Motley Fool's analyst team. But first, let's delve into the world of CRISPR Therapeutics (NASDAQ:CRSP) with Keith Speights.

Now, CRISPR has been a hot stock in 2024, surging more than 100%. However, it's still down 70% from its all-time high, which it reached in November 2021.

After a strong fourth-quarter earnings report in February, enthusiasm for CRISPR has reached new heights. The biotech beat expectations for both earnings and revenue, and it also raised its outlook for the full year.

CRISPR is a leading developer of next-generation gene therapies, using the CRISPR-Cas9 technology to treat serious illnesses. The company's main focus is on treating blood disorders such as beta-